《血吸虫中的蓬勃发展的组学研究》。

Booming Omics in Schistosoma.

机构信息

Department of Medical Parasitology and Mycology, Amiens University Hospital, Amiens, France; Host-Pathogen Interaction Study Group (GEIHP, EA 3142), UNIV Angers, UNIV Brest, Federative Structure of Research 'Cellular Interactions and Therapeutic Applications', SFR 4208 ICAT, Angers, France.

IHPE, University of Montpellier, CNRS, Ifremer, University of Perpignan Via Domitia, Perpignan, France.

出版信息

Trends Parasitol. 2021 Jan;37(1):6-8. doi: 10.1016/j.pt.2020.10.010. Epub 2020 Nov 6.

DOI:10.1016/j.pt.2020.10.010

PMID:33168425

Abstract

Efforts to eliminate schistosomiasis are hindered by incomplete efficacy of the only FDA-approved antischistosomal drug, praziquantel. By using postgenomic technologies, Wendt et al. and Wang et al. deciphered the function of several genes required for worm survival and pathogenesis, which opens the way for the development of innovative parasite-targeted therapies.

摘要

消除血吸虫病的努力受到唯一获得 FDA 批准的抗血吸虫药物吡喹酮疗效不完全的阻碍。通过使用后基因组技术，Wendt 等人和 Wang 等人破译了几种对蠕虫生存和发病机制至关重要的基因的功能，为开发创新的寄生虫靶向疗法开辟了道路。